Per NICE's decision that it's not cost-efficient to spend $400 on a diagnostic test to determine whether a patient should be given Warfarin (see "Why being NICE is deadly"), consider this: conservative estimates project that using the diagnostic (specifically called out in the amended FDA label) will prevent 85,000 serious bleeding events and 17,000 strokes annually – and that’s just in the United States. And this “safer use” is estimated to save $1.1 billion annually. And that’s the mid-range.
NICE should think twice.
NICE should think twice.
